echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use

    Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, Simcere Pharma and Vivoryon Therapeutics of Germany jointly announced that SIM0408, a new drug under development for Alzheimer's disease jointly developed by the two parties in China, has been approved by the Center for Drug Evaluation of the State Drug Administration to enter clinical trials in China
    .

    SIM0408 is a differentiated oral small molecule investigational drug candidate for Alzheimer's disease with the potential to address multiple key AD pathological mechanisms in a unique mode, including Aβ pathology, neuroinflammation and synaptic damage
    .

    SIM0408 blocks glutaminyl cyclase (QPCT) action associated with AD pathology
    .
    The enzyme, which is present in much higher levels in the brains of AD patients than in healthy individuals, catalyzes the formation of N3pE amyloid

    .
    This is a highly neurotoxic variant of the Aβ peptide characteristic of AD patient brains that may act as a seed for Aβ aggregation leading to the formation of highly neurotoxic soluble pE-Aβ oligomers (pE-AβO) and ultimately Nerve plaques, causing cognitive decline in AD patients

    .
    The mechanism of action of SIM0408 is located in the same pathway as some current popular AD therapies, but the mechanism of action is more upstream, aiming to prevent the formation of more neurotoxic N3pE-Aβ and Aβ oligomer (Aβ oligomer) before plaque formation

    .
    Second, the enzymatic activity of glutaminyl cyclase is associated with the pro-inflammatory protein CCL2

    .
    QPCTL, an isoenzyme of QPCT, upregulates CCL2 by converting it to pE-CCL2

    .
    Therefore, blocking QPCTL has the potential to reduce neuroinflammation

    .
    In addition, CCL2 is a promoter of tau pathology, which in turn is associated with synaptic damage

    .
    Aroglutamstat is able to target these pathologies simultaneously and, compared to many other investigational AD drugs (antibodies that must be injected or infused), is available in oral tablets for ease of administration

    .

    Reference source: [1] Simcere official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.